Literature DB >> 15474004

Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.

Torsten Meissner1, Eberhard Krause, Uwe Vinkemeier.   

Abstract

Research on the export of proteins and nucleic acids from the nucleus to the cytoplasm has greatly gained from the discovery that the actinobacterial toxin leptomycin B (LMB) specifically inactivates the export receptor chromosomal region maintenance 1 (CRM1). Recently, it was shown that myxobacterial cytotoxins, named ratjadones (RATs), also bind to CRM1 and inhibit nuclear export. However, the reaction mechanism of RATs was not resolved. Here, we show that LMB and RAT A employ the same molecular mechanism to inactivate CRM1. Alkylation of residue Cys528 of CRM1 determines both LMB and RAT sensitivity and prevents nuclear export of CRM1 cargo proteins. Copyright 2004 Federation of European Biochemical Societies

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474004     DOI: 10.1016/j.febslet.2004.08.056

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  32 in total

1.  The anti-inflammatory prostaglandin 15-deoxy-delta(12,14)-PGJ2 inhibits CRM1-dependent nuclear protein export.

Authors:  Mark Hilliard; Cornelia Frohnert; Christiane Spillner; Simone Marcone; Annegret Nath; Tina Lampe; Desmond J Fitzgerald; Ralph H Kehlenbach
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

Review 2.  Controlling protein compartmentalization to overcome disease.

Authors:  James R Davis; Mudit Kakar; Carol S Lim
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

Review 3.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

4.  Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors.

Authors:  Ori Kalid; Dora Toledo Warshaviak; Sharon Shechter; Woody Sherman; Sharon Shacham
Journal:  J Comput Aided Mol Des       Date:  2012-09-30       Impact factor: 3.686

Review 5.  Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.

Authors:  Joel G Turner; Jana Dawson; Christopher L Cubitt; Rachid Baz; Daniel M Sullivan
Journal:  Semin Cancer Biol       Date:  2014-03-12       Impact factor: 15.707

6.  Leukotriene B(4) BLT receptor signaling regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of Ras/Raf/ERK/p42 AUF1 pathway.

Authors:  Beibei Zhai; Huiqing Yang; Arturo Mancini; QingWen He; John Antoniou; John A Di Battista
Journal:  J Biol Chem       Date:  2010-05-19       Impact factor: 5.157

Review 7.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

8.  Balanced nuclear and cytoplasmic activities of EDS1 are required for a complete plant innate immune response.

Authors:  Ana V García; Servane Blanvillain-Baufumé; Robin P Huibers; Marcel Wiermer; Guangyong Li; Enrico Gobbato; Steffen Rietz; Jane E Parker
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

9.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

10.  KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

Authors:  Julia Etchin; Takaomi Sanda; Marc R Mansour; Alex Kentsis; Joan Montero; Bonnie T Le; Amanda L Christie; Dilara McCauley; Scott J Rodig; Michael Kauffman; Sharon Shacham; Richard Stone; Anthony Letai; Andrew L Kung; A Thomas Look
Journal:  Br J Haematol       Date:  2013-02-04       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.